Corvus Pharmaceuticals Stock Price Prediction
| CRVS Stock | USD 2.16 0.05 2.37% |
Oversold Vs Overbought
68
Oversold | Overbought |
Corvus Pharmaceuticals stock price prediction is an act of determining the future value of Corvus Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Corvus Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Corvus Pharmaceuticals and does not consider all of the tangible or intangible factors available from Corvus Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Corvus Pharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Corvus Pharmaceuticals' stock price prediction:EPS Estimate Next Quarter (0.13) | EPS Estimate Current Year (0.48) | EPS Estimate Next Year (0.53) | Wall Street Target Price 7.83 |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Corvus Pharmaceuticals based on different types of headlines from major news networks to social media. The Corvus stock price prediction module provides an analysis of price elasticity to changes in media outlook on Corvus Pharmaceuticals over a specific investment horizon. Using Corvus Pharmaceuticals hype-based prediction, you can estimate the value of Corvus Pharmaceuticals from the perspective of Corvus Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Corvus Pharmaceuticals using Corvus Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Corvus using crowd psychology based on the activity and movement of Corvus Pharmaceuticals' stock price.
Corvus Pharmaceuticals Implied Volatility | 0.0 |
Corvus Pharmaceuticals' implied volatility exposes the market's sentiment of Corvus Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Corvus Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Corvus Pharmaceuticals stock will not fluctuate a lot when Corvus Pharmaceuticals' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Corvus Pharmaceuticals. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Corvus Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Corvus because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Corvus Pharmaceuticals after-hype prediction price | USD 2.15 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Corvus |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Corvus Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Corvus Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Corvus Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Corvus Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Corvus Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Corvus Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Corvus Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Corvus Pharmaceuticals' historical news coverage. Corvus Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.11 and 6.84, respectively. We have considered Corvus Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Corvus Pharmaceuticals is risky at this time. Analysis and calculation of next after-hype price of Corvus Pharmaceuticals is based on 3 months time horizon.
Corvus Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Corvus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corvus Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Corvus Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.15 | 4.72 | 0.02 | 0.00 | 8 Events / Month | 6 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.16 | 2.15 | 0.46 |
|
Corvus Pharmaceuticals Hype Timeline
Corvus Pharmaceuticals is currently traded for 2.16. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.0. Corvus is anticipated to decline in value after the next headline, with the price expected to drop to 2.15. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.46%, whereas the daily expected return is currently at 0.15%. The volatility of related hype on Corvus Pharmaceuticals is about 41955.56%, with the expected price after the next announcement by competition of 2.16. About 45.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. Corvus Pharmaceuticals recorded a loss per share of 0.51. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 8 days. Check out Corvus Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Corvus Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Corvus Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Corvus Pharmaceuticals' future price movements. Getting to know how Corvus Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Corvus Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MREO | Mereo BioPharma Group | (0.09) | 7 per month | 0.00 | (0.02) | 7.09 | (6.75) | 17.85 | |
| TERN | Terns Pharmaceuticals | (0.11) | 8 per month | 0.00 | (0.05) | 7.30 | (8.50) | 27.76 | |
| PDSB | PDS Biotechnology Corp | 0.12 | 10 per month | 0.00 | (0.18) | 7.02 | (9.16) | 26.33 | |
| INZY | Inozyme PharmaInc | (0.12) | 10 per month | 0.00 | (0.11) | 4.80 | (8.37) | 18.48 | |
| HOOK | Hookipa Pharma | (0.02) | 9 per month | 4.88 | 0.02 | 9.88 | (6.17) | 37.03 | |
| XFOR | X4 Pharmaceuticals | 0.04 | 9 per month | 4.58 | 0.04 | 8.06 | (9.09) | 40.83 | |
| DAWN | Day One Biopharmaceuticals | 0.28 | 9 per month | 0.00 | (0.07) | 6.30 | (7.39) | 21.23 | |
| ABOS | Acumen Pharmaceuticals | (0.01) | 8 per month | 0.00 | (0.12) | 7.08 | (5.98) | 19.42 |
Corvus Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Corvus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Corvus using various technical indicators. When you analyze Corvus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Corvus Pharmaceuticals Predictive Indicators
The successful prediction of Corvus Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Corvus Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Corvus Pharmaceuticals based on analysis of Corvus Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Corvus Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Corvus Pharmaceuticals's related companies. | 2021 | 2023 | 2024 (projected) | Current Ratio | 5.65 | 4.07 | 3.87 | Net Debt To EBITDA | 1.38 | 0.48 | 0.46 |
Story Coverage note for Corvus Pharmaceuticals
The number of cover stories for Corvus Pharmaceuticals depends on current market conditions and Corvus Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Corvus Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Corvus Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Corvus Pharmaceuticals Short Properties
Corvus Pharmaceuticals' future price predictability will typically decrease when Corvus Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Corvus Pharmaceuticals often depends not only on the future outlook of the potential Corvus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Corvus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48 M | |
| Cash And Short Term Investments | 27.1 M |
Check out Corvus Pharmaceuticals Basic Forecasting Models to cross-verify your projections. For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Corvus Stock analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Corvus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corvus Pharmaceuticals. If investors know Corvus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corvus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Corvus Pharmaceuticals is measured differently than its book value, which is the value of Corvus that is recorded on the company's balance sheet. Investors also form their own opinion of Corvus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corvus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corvus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corvus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corvus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corvus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corvus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.